Effect of norepinephrine synthesis inhibitors and a dopamine agonist on hypothalamic LH-RH serum gonadotrophin and prolactin levels in gonadal steroid treated rats.
D000818:Animals; D002369:Castration; D004050:Ditiocarb / Q000494:pharmacology*; D004873:Ergolines / Q000494:pharmacology*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000378:metabolism*; D007987:Gonadotropin-Releasing Hormone / Q000378:metabolism*; D007030:Hypothalamo-Hypophyseal System; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D010668:Phenylthiazolylthiourea / Q000494:pharmacology*; D010670:Phenylthiourea / Q000031:analogs & derivatives*; D011374:Progesterone / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D051381:Rats; D013859:Thiocarbamates / Q000494:pharmacology*
D004873:Ergolines; D013859:Thiocarbamates; D010668:Phenylthiazolylthiourea; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D010670:Phenylthiourea; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D004050:Ditiocarb